BTEK:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP)

ETF | Others |

Last Closing

USD 4.9705

Change

-0.08 (-1.53)%

Market Cap

N/A

Volume

7.97K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-25 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-1.85 (-0.70%)

USD 292,109.69B
XNIF:LSE Xtrackers Nifty 50 Swap UCITS ..

-119.50 (-0.59%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

-9.00 (-4.44%)

USD 1,607.29B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.42 (-2.27%)

USD 701.81B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.34 (-2.34%)

USD 636.56B
0R1I:LSE NVIDIA Corp.

-4.18 (-3.68%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.25 (+0.35%)

USD 266.08B
PRJU:LSE Amundi Index Solutions - Amund..

-0.63 (-2.05%)

USD 259.48B
0QZO:LSE 0QZO

-2.40 (-2.39%)

USD 258.54B

ETFs Containing BTEK:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.30% 41% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.30% 40% F 45% F
Trailing 12 Months  
Capital Gain -1.11% 23% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.11% 20% F 35% F
Trailing 5 Years  
Capital Gain -98.72% 2% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.72% 2% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -2.08% 12% F 24% F
Dividend Return -2.08% 11% F 23% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 22.45% 25% F 40% F
Risk Adjusted Return -9.28% 16% F 26% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.